Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
AM-Pharma logo — AM-Pharma’s ilofotase alfa is being developed as potential e...

AM-Pharma

AM-Pharma’s ilofotase alfa is being developed as potential enzyme replacement therapy for adult hypophosphatasia pts

Founded 2002 The Netherlands The Netherlands 31 employees Venture round Total: $207.54M Biopharma, Biotechnology +2

General Information

Company Name AM-Pharma
Founded Year 2002
Location The Netherlands The Netherlands
Employees 31
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with AM-Pharma. To contact AM-Pharma, visit am-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AM-Pharma compare?

A PDF of AM-Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AM-Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AM-Pharma

AM-Pharma is a clinical stage biopharmaceutical company based in The Netherlands, focusing on the development of a treatment for acute kidney injury. Established in 2000, the company has been making significant strides in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. Recently, on 01 July 2021, the company secured a Venture Round investment from Euazeo, a clear indication of its promising prospects. AM-Pharma BV's core focus lies in the development of recombinant Alkaline Phosphatase for clinical use, positioning it at the forefront of innovation in the biopharmaceutical space. With its dedicated efforts and strategic partnerships, AM-Pharma is forging a path towards revolutionizing the treatment of acute kidney injury and garnering attention from potential investors and industry leaders.

Business keywords: Biopharmaceutical, Clinical Stage, Therapeutics, Acute Kidney Injury, Inflammatory Diseases, Infectious Diseases, Recombinant Alkaline Phosphatase, Clinical Development, Ulcerative Colitis, Hospital-Acquired Infections, Biotech, Sepsis, Drug Development, Netherlands, AM-Pharma BV

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Euazeo
Euazeo
01 Jul 2021
Venture Round €23.00M 8
IDInvest Partners Kurma Partners Forbion
IDInvest Partners, Kurma Partners +6
31 Mar 2020
Debt Financing €24.00M 1
European Investment Bank
31 Mar 2020
Series F €116.00M 8
IDInvest Partners Kurma Partners Forbion
IDInvest Partners, Kurma Partners +6
16 Jul 2019
Corporate Round Undisclosed 1
Pfizer
11 May 2015
Series E €12.20M 6
Kurma Partners Gilde Healthcare AbbVie Ventures
Kurma Partners, Gilde Healthcare +4
11 Sep 2014
Series D €29.20M 4
IDInvest Partners Kurma Partners BB Biotech Ventures
IDInvest Partners, Kurma Partners +2
13 Sep 2011
Venture Round Undisclosed 1
IDInvest Partners
IDInvest Partners
11 Aug 2011
Series C €2.50M 2
Forbion Inventages
Forbion, Inventages
07 Aug 2007
Series B Undisclosed 2
Biopartners Capital, ABN AMRO Fund
26 Feb 2002

View All 11 Funding Rounds

AM-Pharma Alternatives & Competitors

View All Alternatives
AM-Pharma vs
Antios Therapeutics
Antios Therapeutics United States

Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing therapies fo...

1 employees
Biopharma, Biotechnology
Compare AM-Pharma vs Antios Therapeutics
AM-Pharma vs
Palisade Bio
Palisade Bio United States

Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complic...

Post-IPO Debt
15 employees
Biopharma, Biotechnology
Compare AM-Pharma vs Palisade Bio
AM-Pharma vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About AM-Pharma

AM-Pharma’s ilofotase alfa is being developed as potential enzyme replacement therapy for adult hypophosphatasia pts
AM-Pharma was founded in 2002.
AM-Pharma is headquartered in The Netherlands.
AM-Pharma operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Clinical Stage, Therapeutics and Acute Kidney Injury.
AM-Pharma has approximately 31 employees.
AM-Pharma has completed 11 funding rounds, raising a total of $207.54M. The latest funding stage is Venture round.
Top alternatives and competitors to AM-Pharma include Antios Therapeutics, Palisade Bio, Entero Therapeutics (Nasdaq: ENTO), Spero Therapeutics, Kynos Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AM-Pharma and Antios Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AM-Pharma, https://bouncewatch.com/company/am-pharma, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes